About Central Precocious Puberty

Central precocious puberty, or CPP, is the term for puberty that starts earlier than usual. That is, before age 8 in girls or age 9 in boys.  Central precocious puberty can even begin in infancy. The condition occurs in 1 out of every 5,000 to 10,000 children, and is much more common in girls than in boys.1

In most cases, the cause of CPP, also called "true" central precocious puberty is unknown. Fortunately, there are medicines called GnRH (gonadotropin releasing hormone) agonists. GnRH agonists can help stop the progression of early puberty (caused by CPP) by lowering the level of puberty-causing hormones that your child's body is making.

Next: Signs and Symptoms of Central Precocious Puberty

References:
1. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004;6(4):211-231.

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

  • SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

  • Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

  • During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.